Identification and targeting of selective vulnerability rendered by tamoxifen resistance

BACKGROUND: The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast cancer, the acquired resistance to TMX anti-estrogen therapy is the main hurdle...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Madhurendra, Zhou, Xiaolei, Chen, Xinsong, Santos, Gema Sanz, Peuget, Sylvain, Cheng, Qing, Rihani, Ali, Arnér, Elias S. J., Hartman, Johan, Selivanova, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388523/
https://www.ncbi.nlm.nih.gov/pubmed/32727562
http://dx.doi.org/10.1186/s13058-020-01315-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388523/
https://www.ncbi.nlm.nih.gov/pubmed/32727562
http://dx.doi.org/10.1186/s13058-020-01315-5

Ejemplares similares